Clinical trials: Co-Infection HIV-HCV
Hepatitis C Infection With HIV Co-Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with acute genotype 1 or 4 hepatitis C virus (HCV)…
- Trial name
- NCT02457611
- Testing
- LDV/SOF
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
HIV Infections, Hepatitis C
Effects of HIV and Hepatitis C Virus on the Brain
This study will determine the effects that HIV and hepatitis C virus have on thinking abilities and whether the viruses affect brain chemistry.
- Trial name
- NCT00494936
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
HIV Coinfection
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.
- Trial name
- NCT01327547
- Testing
- Maraviroc
- Where
- 48 sites in United States, Czechia and 7 more
- Volunteers
- 138 people
- Sponsor
- ViiV Healthcare
HCV HIV
Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia
Background: Treatment for Hepatitis C has changed a lot in the past 2 years. Most of this change comes from a combination of medicines that is yielding high cure rates. But its long-term effects are uncertain.
- Trial name
- NCT02339038
- Testing
- Ledipasvir 90 mg and Sofosbuvir 400 mg
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV, Hepatitis C, Chronic
Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection
Effective all-oral medications are finally available to cure hepatitis C virus, which affects more than 4 million Americans and one-in-four people living with HIV.
- Trial name
- Care2Cure (NCT02707991)
- Testing
- Nurse Case Management
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Johns Hopkins University
Hepatitis C, Hiv
Zepatier in Patients with Substance Use
The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or…
- Conditions
- Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders
- Trial name
- NCT04048850
- Testing
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Illinois Chicago
HIV Infections, Hepatitis C
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
This study will test the safety and effectiveness of a new treatment for hepatitis C (HCV) in patients who also have HIV. The usual treatment for HCV in people who are not HIV-infected is interferon-alfa (IFN) with ribavirin…
- Trial name
- NCT00015652
- Testing
- Ribavirin, Aldesleukin, Peginterferon alfa-2b
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Thrombocytopenia, Hepatitis C
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Thrombocytopenia occurs when a person's blood has a decreased number of platelets, which are cells involved in blood clotting. This condition may lead to uncontrolled bleeding and can be fatal.
- Conditions
- Thrombocytopenia, Hepatitis C, HIV Infections
- Trial name
- NCT00239733
- Testing
- Anti-D
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Evaluation Study of RDTs Detecting Antibodies Against HCV
The study aims to evaluate 13 different HCV RDTs (10 on-market, 3 under development) for their diagnostic performance and operational characteristics in archived EDTA plasma samples, originating from patients from different…
- Trial name
- NCT04033887
- Testing
- 13 Rapid Diagnostic Tests and reference tests
- Where
- 3 sites in Belgium, Georgia and 1 more
- Volunteers
- 1,710 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
HIV, Hepatitis C, Chronic
The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients
The purpose of this research study is to explore what role immune cells within the gut (the sigmoid colon) have locally and on the immune system of patients infected with HCV, HIV or HCV/ HIV co-infection.
- Conditions
- HIV, Hepatitis C, Chronic, HCV Coinfection
- Trial name
- NCT01335230
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
HIV Infection, Hepatitis C
Improving Fibrosis Outcomes With Metformin
This study will evaluate the role of Metformin on liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance receiving DAA HCV treatment.
- Trial name
- NCT02306070
- Testing
- Metformin, No metformin treatment
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Hepatitis C and HIV Coinfection
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir
This study evaluates the effect of sofosbuvir/ledipasvir (SOF/LDV) treatment on the pharmacokinetics (PK) and renal safety of tenofovir.
- Trial name
- NCT02588287
- Testing
- Blood draws for tenofovir PK, renal function
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Colorado, Denver
HIV Infections, Hepatitis C
Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection
To show the feasibility of liver transplantation in HCV-HIV coinfected patients. To study the two-year survival after transplantation, the interaction between HCV and HIV after transplantation, the influence of HIV on HCV…
- Trial name
- NCT00158535
- Testing
- liver transplantation
- Where
- France
- Volunteers
- 15 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Human Immunodeficiency Virus
Treatment of Acute Hepatitis C Virus in HIV Co-Infection
This study is designed to test the hypothesis that treatment of hepatitis C virus (HCV) infection during the first 6 months after acquiring HCV among people who already have pre-existing HIV infection will result in improved…
- Conditions
- Hepatitis C, Human Immunodeficiency Virus, HIV Infections
- Trial name
- NCT00845676
- Testing
- Pegylated interferon alfa-2a + Ribavirin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Hepatitis C, HIV
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
This study consists of 2 parts, Part A and Part B. Part A, the Phase 1 drug interaction/early viral kinetic study, will evaluate the effect of selected antiretroviral therapies on the safety, viral kinetics, and pharmacokinetics…
- Trial name
- NCT01565889
- Testing
- SOF, EFV/FTC/TDF, EFV
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences
Healthy
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction, safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and Tenofovir disoproxil fumarate (part 1) and…
- Trial name
- NCT03537404
- Testing
- Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- R-Pharm
HIV Infections, Hepatitis C
Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
A study concerning viral kinetic with 10 co-infected HIV-HCV patients on treatment with peginterferon alfa-2a + ribavirin o IFN + ribavirin was reported in Conference on Retroviruses and Opportunistic Infections 2002 by Dr.
- Trial name
- NCT00612755
- Testing
- Peginterferon alfa-2a + ribavirin
- Where
- 19 sites in Spain
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Hospital Clinico Universitario San Cecilio
HIV-HCV
Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
Chronic hepatitis C virus (HCV) infection is a major public health problem with an estimated 180 million people infected worldwide.
- Trial name
- NCT02124044
- Testing
- Asunaprevir and Daclatasvir, Asunaprevir and Daclatasvir with BMS-791325
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatitis B, Hepatitis C
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
Background: Hepatitis B and hepatitis C can cause liver damage. They can also cause serious illness, including liver cancer, and even death. This study will follow people who have hepatitis B or hepatitis C.
- Conditions
- Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
- Trial name
- NCT01350648
- Where
- 2 sites in United States
- Volunteers
- 569 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatitis C, HIV Infections
Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP)
Hepatitis C and HIV infect worldwide millions of people leading to a high rate of coinfected patient with eventually liver cirrhosis and endstage liver disease.
- Trial name
- NCT00150904
- Testing
- venous blood puncture
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- UMC Utrecht